Stevens Capital Management’s NovoCure NVCR Stock Holding History

Stevens Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-9,064	Closed	-$678K	–	742
2019 Q3	$678K	Buy	+9,064	New	+$725K	0.06%	300
2019 Q2	–	Sell	-38,647	Closed	-$1.86M	–	786
2019 Q1	$1.86M	Buy	38,647 +18,654	+93%	+$898K	0.08%	282
2018 Q4	$669K	Buy	+19,993	New	+$731K	0.03%	451

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Stevens Capital Management's NVCR Position: Q4 2019 in Review

Stevens Capital Management sold out of NovoCure (NVCR) in Q4 2019, closing a stake of 9,064 shares — an estimated $678K sold.

Stevens Capital Management first reported a position in NVCR in Q4 2018 and held it in 3 quarters. The position peaked at $1.86M in Q1 2019. 262 funds tracked by Wall St. Rank hold NVCR as of Q4 2019.

Stevens Capital Management reported no remaining NovoCure position as of Q4 2019 after selling out during the quarter.
Stevens Capital Management sold 9,064 NovoCure shares in Q4 2019, an estimated $678K.
Stevens Capital Management first reported a position in NovoCure in Q4 2018 and held it in 3 quarters.
Stevens Capital Management's NovoCure position peaked at $1.86M in Q1 2019.
262 funds tracked by Wall St. Rank held NovoCure as of Q4 2019.

Based on Stevens Capital Management's 13F filing for Q4 2019, filed 6 Feb 2020.